G J Lappin

Summary

Country: UK

Publications

  1. pmc The phase 0 microdosing concept
    R Colin Garner
    Xceleron Ltd, York Biocentre, Heslington, York, UK
    Br J Clin Pharmacol 61:367-70. 2006
  2. ncbi request reprint Absorption, metabolism and excretion of 4-chloro-2-methylphenoxyacetic acid (MCPA) in rat and dog
    G J Lappin
    Covance Laboratories Ltd, Harrogate, UK
    Xenobiotica 32:153-63. 2002
  3. ncbi request reprint Big physics, small doses: the use of AMS and PET in human microdosing of development drugs
    Graham Lappin
    Xceleron Ltd, York Biocentre, Innovation Way, Heslington, York YO10 5NY, UK
    Nat Rev Drug Discov 2:233-40. 2003
  4. ncbi request reprint Positron emission tomography for use in microdosing studies
    Claudia Christina Wagner
    Department of Clinical Pharmacology, Medical University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Curr Opin Drug Discov Devel 11:104-10. 2008
  5. ncbi request reprint The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers
    Nenad Sarapa
    Clinical Pharmacology, Pfizer Global Research and Development, San Diego, CA, USA
    J Clin Pharmacol 45:1198-205. 2005
  6. ncbi request reprint The use of isotopes in the determination of absolute bioavailability of drugs in humans
    Graham Lappin
    Xceleron Ltd, York Biocentre, Innovation Way, York, YO10 5NY, UK
    Expert Opin Drug Metab Toxicol 2:419-27. 2006
  7. ncbi request reprint The use of accelerator mass spectrometry to obtain early human ADME/PK data
    Graham Lappin
    Xceleron Ltd, York Biocentre, Innovation Way, Heslington, York YO10 5NY, UK
    Expert Opin Drug Metab Toxicol 1:23-31. 2005
  8. ncbi request reprint Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs
    Graham Lappin
    Xceleron, York Biocentre, Innovation Way, Heslington, York YO10 5NY, United Kingdom
    Clin Pharmacol Ther 80:203-15. 2006

Collaborators

Detail Information

Publications8

  1. pmc The phase 0 microdosing concept
    R Colin Garner
    Xceleron Ltd, York Biocentre, Heslington, York, UK
    Br J Clin Pharmacol 61:367-70. 2006
  2. ncbi request reprint Absorption, metabolism and excretion of 4-chloro-2-methylphenoxyacetic acid (MCPA) in rat and dog
    G J Lappin
    Covance Laboratories Ltd, Harrogate, UK
    Xenobiotica 32:153-63. 2002
    ....
  3. ncbi request reprint Big physics, small doses: the use of AMS and PET in human microdosing of development drugs
    Graham Lappin
    Xceleron Ltd, York Biocentre, Innovation Way, Heslington, York YO10 5NY, UK
    Nat Rev Drug Discov 2:233-40. 2003
    ..Microdosing allows safer human studies as well as reducing the use of animals in preclinical toxicology...
  4. ncbi request reprint Positron emission tomography for use in microdosing studies
    Claudia Christina Wagner
    Department of Clinical Pharmacology, Medical University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Curr Opin Drug Discov Devel 11:104-10. 2008
    ..Situated at the interface of preclinical and clinical drug testing, PET microdosing is a powerful and highly innovative tool for pharmaceutical development...
  5. ncbi request reprint The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers
    Nenad Sarapa
    Clinical Pharmacology, Pfizer Global Research and Development, San Diego, CA, USA
    J Clin Pharmacol 45:1198-205. 2005
    ..Accelerator mass spectrometry microdosing reduces potential safety issues around dosing radioactivity to humans and prevents the need to formulate high intravenous doses...
  6. ncbi request reprint The use of isotopes in the determination of absolute bioavailability of drugs in humans
    Graham Lappin
    Xceleron Ltd, York Biocentre, Innovation Way, York, YO10 5NY, UK
    Expert Opin Drug Metab Toxicol 2:419-27. 2006
    ..Isotopic labelling not only allows for the accurate and efficient determination of absolute bioavailability, but can also provide information on first-pass effects and other pharmacokinetic parameters...
  7. ncbi request reprint The use of accelerator mass spectrometry to obtain early human ADME/PK data
    Graham Lappin
    Xceleron Ltd, York Biocentre, Innovation Way, Heslington, York YO10 5NY, UK
    Expert Opin Drug Metab Toxicol 1:23-31. 2005
    ..AMS also enables other studies such as absolute bioavailability to be conducted earlier if required...
  8. ncbi request reprint Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs
    Graham Lappin
    Xceleron, York Biocentre, Innovation Way, Heslington, York YO10 5NY, United Kingdom
    Clin Pharmacol Ther 80:203-15. 2006
    ..Each compound was chosen to represent a situation in which prediction of pharmacokinetics from either animal or in vitro studies (or both) was or is likely to be problematic...